Shares of Moderna was surging in early Wednesday trading after the pharmaceutical company said it reached a deal to resolve a ...

By Kamal Choudhury and Blake Brittain March 3 (Reuters) - Moderna has agreed to pay Genevant Sciences, a subsidiary of ...

Moderna to pay $950 million with no future royalties to resolve all global litigation; corresponding charge expected in ...

Here are some of the stocks making notable moves in Wednesday's premarket action: Moderna shares are up more than 5% after ...

Including the settlement payment, Moderna now expects to end 2026 with between $4.5 billion and $5 billion in cash and cash ...

The company will appeal to a federal circuit court to argue that it has limited liability due to its status as a government ...

Moderna (MRNA) stock jumped 8.7% after announcing a $950M patent settlement with Arbutus and Genevant, the largest pharma patent deal ever recorded.

Europe's medicines regulator recommended approval for Moderna's COVID and flu combination vaccine on Friday, putting it on track to become the first single shot to ...

A settlement provides a massive windfall for Arbutus and Roivant and avoids a worst-case scenario for Moderna.

Moderna Inc MRNA shares are rising in Tuesday’s after-hours session after the company announced it reached a settlement agreement with Arbutus Biopharma and Genevant Sciences. Moderna shares are ...

The European Medicines Agency (EMA) announced Friday it has recommended Moderna’s combined mRNA COVID-19 and flu vaccine be ...

The US Food and Drug Administration has reversed course and will review a new mRNA flu vaccine from Moderna, the ...